For Health Centers

Make your checkups see earlier.

PANCREASaver® provides AI-assisted review of eligible abdominal CT studies for screening programs, subject to clinical protocols and local regulations.

Program rationale

Why add AI-assisted pancreatic CT review to your program?

Pancreatic cancer may cause few or nonspecific symptoms early. Screening programs should use clear clinical protocols, eligibility criteria, and referral pathways.

Clear program criteria

A screening program should use current local epidemiology, clear eligibility criteria, and defined referral pathways.

Fits existing services

Add an AI-assisted pancreatic CT review option to eligible programs while keeping radiologist review and existing referral processes.

Documented evidence

Taiwan TFDA medical device license No. 007946, FDA Breakthrough Device Designation, and published study results including a nationwide, multicenter AUC of 0.95.

Integration

An illustrative four-week path from contract to go-live

A dedicated project manager throughout; radiologist and technologist training included.

1

Week 1 · Assessment

Review equipment (CT model, PACS version) and workflow; define report format and alert rules.

2

Week 2 · Integration

AI server setup and PACS/RIS interfacing; DICOM routing is configured within the institution’s workflow.

3

Week 3 · Validation & training

Validation on institutional data plus training for radiologists and technologists (online course included).

4

Week 4 · Go-live

Go-live, pilot run, performance dashboard delivered. Monthly quality reports thereafter.

Radiology workflow

Radiologists decide; AI adds a review cue

PANCREASaver® is designed to fit radiologist review workflows by flagging suspicious findings for closer evaluation.

①

Scan complete

CT scan finishes; images are analyzed by AI in the background (~60–90 seconds).

②

AI annotation and alert

Suspicious findings are flagged side-by-side with the original images for the radiologist's review.

③

Follow-up suggestion

For studies with flagged findings, the system supports follow-up review according to the institution’s protocol.

Real-world numbers

Validated in real settings

92.1%
Sensitivity for tumors under 2 cm
0.95
Multicenter AUC
5,500+
Cumulative patient cases (research & commercial use)
10
Patents (Taiwan and U.S.)
Performance metric Value Source
Sensitivity for tumors < 2 cm92.1%Lancet Digital Health 2020 ↗
Specificity92.8%Lancet Digital Health 2020 ↗
Nationwide multicenter AUC (n=1,473)0.95Radiology 2023 ↗
Cumulative patient cases (research & commercial use)5,500+Company usage totals (2026-10-13)

Add AI-assisted pancreatic CT review to your program

Leave your contact and our team will reach out within two business days.

Request the program